ReviewFuture microbiology2012
Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis.
Review in Future microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 1 synthesis or guideline pooled it, 265 citations in OpenAlex.
- Whole Genome Sequencing and Comparative Genomics of the Emerging PathogenPathogens (Basel, Switzerland) · 2025Pooled it
- SmartVax-Bp: An Immunoinformatic guided Multi-Epitope Vaccine Blueprint Against Burkholderia pseudomallei.Probiotics and antimicrobial proteins · 2026Article
- Discovery of repurposed drugs that disrupt intracellular replication of Burkholderia pseudomallei and Burkholderia mallei and protect against lethal aerosol infection.PLoS pathogens · 2026Article
- Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim-Sulfamethoxazole Resistance in Burkholderia thailandensis.ACS infectious diseases · 2026Article
- Melioidosis Complicated by Native Valve Endocarditis in a Traveler Returning From Thailand to the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Disseminated melioidosis due to ceftazidime-resistant Burkholderia pseudomallei in a Spanish traveler.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Hospital-Based Cross-Sectional Study ofGeoHealth · 2026Article
- Drug screening to identify compounds to eliminateiScience · 2026Article
- Genetic Engineering of Lysogenic-Lytic Switch Genes ImprovesInternational journal of molecular sciences · 2026Article
- Substrate specificity of Burkholderia pseudomallei multidrug transporters is influenced by the hydrophilic patch in the substrate-binding pocket.FEBS letters · 2026Article
- Meropenem treatment failure in severe melioidosis despite in vitro susceptibility: A case report.IDCases · 2026Article
- Phage-mediated control of melioidosis in Southern China: molecular insights and therapeutic potential of N4-like viruses from Hainan.BMC microbiology · 2025Article
- Genomic characterization of an environmental Burkholderia thailandensis strain from Kerala, India reveals virulence and antimicrobial resistance signatures.BMC genomics · 2025Article
- New Frontiers for Old Medications: Repurposing Approved Drugs Against Gram-Negative Bacterial Infections.Microorganisms · 2025Review
- Genomic insights into ceftazidime resistance inAntimicrobial agents and chemotherapy · 2025Article
- Rapid detection of antibiotic resistance in Burkholderia pseudomallei using MALDI-TOF mass spectrometry.Scientific reports · 2025Article
- Global Prevalence of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Article
- Evolutionary Dynamics and Functional Differences in Clinically Relevant Pen β-Lactamases fromJournal of chemical information and modeling · 2025Article
- Rare Neuromelioidosis Case that Required Long Intensive Phase Therapy.Oman medical journal · 2025Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Burkholderia pseudomallei is the etiologic agent of melioidosis. This multifaceted disease is difficult to treat, resulting in high morbidity and mortality. Treatment of B. pseudomallei infections is lengthy and necessitates an intensive phase (parenteral ceftazidime, amoxicillin-clavulanic acid or meropenem) and an eradication phase (oral trimethoprim-sulfamethoxazole). The main resistance mechanisms affecting these antibiotics include enzymatic inactivation, target deletion and efflux from the cell, and are mediated by chromosomally encoded genes. Overproduction and mutations in the class A PenA β-lactamase cause ceftazidime and amoxicillin-clavulanic acid resistance. Deletion of the penicillin binding protein 3 results in ceftazidime resistance. BpeEF-OprC efflux pump expression causes trimethoprim and trimethoprim-sulfamethoxazole resistance. Although resistance is still relatively rare, therapeutic efficacies may be compromised by resistance emergence due to increased use of antibiotics in endemic regions. Novel agents and therapeutic strategies are being tested and, in some instances, show promise as anti-B. pseudomallei infectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.